Tissue catabolism and donor-specific dexamethasone response in a human osteochondral model of post-traumatic osteoarthritis
Abstract Background Post-traumatic osteoarthritis (PTOA) does not currently have clinical prognostic biomarkers or disease-modifying drugs, though promising candidates such as dexamethasone (Dex) exist. Many challenges in studying and treating this d...
Main Authors: | Black, Rebecca M., Flaman, Lisa L., Lindblom, Karin, Chubinskaya, Susan, Grodzinsky, Alan J., Önnerfjord, Patrik |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biological Engineering |
Format: | Article |
Language: | English |
Published: |
BioMed Central
2022
|
Online Access: | https://hdl.handle.net/1721.1/143088 |
Similar Items
-
Dexamethasone: chondroprotective corticosteroid or catabolic killer?
by: Black, Robert Xavier, et al.
Published: (2020) -
Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage: relevance to post-traumatic osteoarthritis
by: Chubinskaya, S., et al.
Published: (2017) -
Proteomic analysis reveals dexamethasone rescues matrix breakdown but not anabolic dysregulation in a cartilage injury model
by: Black, Rebecca Mae, et al.
Published: (2022) -
Proteomic analysis reveals dexamethasone rescues matrix breakdown but not anabolic dysregulation in a cartilage injury model
by: Black, Rebecca Mae, et al.
Published: (2021) -
Sustained intra-cartilage delivery of low dose dexamethasone using a cationic carrier for treatment of post traumatic osteoarthritis
by: De la Vega, RE, et al.
Published: (2018)